Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib PK in renal impairment
NCT03542305Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time and Maximum Observed Plasma Concentration. Started Aug 2018; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03542305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542305.